Randomized controlled trial shows 2 years of therapy stabilizes cognition.

"Hidden" source should not be ignored in patients receiving multiple agents.

Atabecestat data contribute to concerns about β-secretase inhibitors.

Nationwide study finds a dose-dependent risk reduction.

Results changed drug therapy and/or counseling in more than 60% of patients.

Results from the HOPE-3 trial.

Swedish cohort study finds nearly tripled dementia risk, regardless of stroke history.

A comparison of 7 short variants of the MoCA for diagnosing MCI and dementia.

The highest risk was observed during the first month of use.

All atypical antipsychotics offer only minimal benefit over placebo.

Dutch study finds objective impairments in varied domains.

Study shows no evidence for an interaction between the two.

Findings from a long-term prospective cohort study.

Large, long-term cohort study finds healthier eating is not protective.